ePoster · Neuroscience
Stefan Mihalas, Matthew Bull, Jacob Sacks, Marton Rozsa, Christina Wang, Karel Svoboda, Matthew Golub, Kyle Aitken, Kayvon Daie · COSYNE 2025
The process of learning requires the brain to generate new activity patterns, yet it has been known for some time that the learning speed of certain behaviors can vary significantly. Brain computer interfaces (BCIs) offer a promising setup to study learning since they allow one to concretely link changes in activity to task performance. Using a BCI-driven center-out task, Sadtler et. al. (2014) showed that the speed of learning new activity patterns can differ significantly depending on their relation to Rhesus macaque’s intrinsic neural activity. A mapping between how individual synapses adju
ePoster · Neuroscience
Jelena Podgorac Kojadinovic · FENS Forum 2024
Introduction: The rational polytherapy of epilepsy during pregnancy is challenging. VPA represents an old antiepileptic with broad spectrum indications and LEV is relatively new antiepileptic used for the treatment of generalized tonic-clonic and juvenile myoclonic epilepsy and adjunctive therapy for focal seizures. Combination of these two antiepileptics during pregnancy, according to the cohort study (Gašparović at al., 2020), was the most common. Aim: The aim of the present study was to assesse the behavioral performance of the mice whose mothers were treated with combination of VPA and LEV
ePoster · Neuroscience
Marie Vionnet, Denis Mariolle, Istvan Horvath, Ranjeet Kumar, Pernilla Wittung-Stafshede, Christel Marquette, Jenny Molet · FENS Forum 2024
Parkinson’s disease (PD) is the secondary neurodegenerative disease around the world, affecting more than 6,5 million people. This disease is characterized by a myriad of motor and non motor dysfunctions that worsen over time. Until now, the disease etiology remains unclear, partly because existing PD animal models fail to mimick the physiopathology. Based on the administration of a pathogenic protein (alpha-synuclein) playing a key role in PD, a mouse model has recently been developed at Clinatec (CEA Grenoble) presenting chronic and progressive symptoms that aggravate over time. Neuroprotect